Emerging technology and platforms for cardiotoxicity testing
- PMID: 33017593
- PMCID: PMC7747951
- DOI: 10.1016/j.taap.2020.115262
Emerging technology and platforms for cardiotoxicity testing
Abstract
Keywords: Anticancer drugs; Cardiomyocyte; Embryonic stem cells; High throughput; Human-induced pluripotent stem cells; Toxicity.
Conflict of interest statement
Declaration of Competing Interest
TMAM, holds equities in Tenaya Therapeutics. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Food and Drug Administration or the American Heart Association.
References
-
- Cheng W, Yang S, Li X, Liang F, Zhou R, Wang H, Feng Y, Wang Y, 2020. Low doses of BPA induced abnormal mitochondrial fission and hypertrophy in human embryonic stem cell-derived cardiomyocytes via the calcineurin-DRP1 signaling pathway: a comparison between XX and XY cardiomyocytes. Toxicol. Appl. Pharmacol 388, 114850. - PubMed
-
- Dockery DW, Pope CA III, Xu X, Spengler JD, Ware JH, Fay ME, Ferris BG Jr., Speizer FE, 1993. An association between air pollution and mortality in six U.S. cities. N.Engl.J.Med 329, 1753–1759. - PubMed
-
- Hasinoff BB, Patel D, Wu X, 2020. A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibition. Toxicol. Appl. Pharmacol 399, 115038 http://www.who.int/mediacentre/factsheets/fs317/en/. - PubMed
-
- Miller JM, Meki MH, Ou Q, George SA, Gams A, Abouleisa RRE, Tang XL, Ahern BM, Giridharan GA, El-Baz A, Hill BG, Satin J, Conklin DJ, Moslehi J, Bolli R, Ribeiro AJS, Efimov IR, Mohamed TMA, 2020. Heart slice culture system reliably demonstrates clinical drug-related cardiotoxicity. Toxicol. Appl. Pharmacol 406, 115213. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources